Found 28 results

2010
PROGRESS Collaborative Group, Writing Committee, Arima H, Tzourio C, Anderson C, Woodward M, Bousser MB, Macmahon S, Neal B, Chalmers J.  2010.  Effects of perindopril-based blood pressure lowering on probable cerebral amyloid angiopathy-related intracerebral hemorrhage: the PROGRESS trial. Stroke. 41 :394-6.[IF6.499].
Anderson C.  2010.  More indirect evidence of potential neuroprotective benefits of angiotensin receptor blockers. Journal of Hypertension. 28:429.[IF5.132].
PROGRESS Collaborative Group, Writing Committee, Arima H, Anderson C, Omae T, Liu L, Tzourio C, Woodward M, Macmahon S, Neal B et al..  2010.  Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. Journal of Hypertension. 28 :395-400.[IF5.132].
2009
Dufouil C, Godin O, Chalmers J, Coskun O, Macmahon S, Tzourio-Mazoyer N, Bousser MG, Anderson C, Mazoyer B, Tzourio C.  2009.  Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke . 40:2219-21.[IF6.296]..
Foroud T, Sauerbeck L, Brown R, Anderson C, Woo D, Kleindorfer D, Flaherty ML, Deka R, Hornung R, Meissner I et al..  2009.  Genome screen in familial intracranial aneurysm. BMC Med Genet. 10:Art. No. 3. [IF 2.419]
ONTARGET Investigators, Writing Committee, Cukierman-Yaffe T, Teo K, Jackson S, Anderson C, Sleight P, Hillbrich L, Gerstein H, Yusuf S.  2009.  Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND . Diabetes Res Clin Pract. 83:387-93.[IF1.823].
Young A, Jennings G, Anderson C, Cowan B.  2009.  The Cardiac MRI Substudy to ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND): Analysis protocol and baselin. Clin Res Cardiol. In press, accepted 17 March. [IF 1.442]
Cowan BR, Young AA, Anderson C, Doughty RN, Krittayaphong R, Lonn E, Marwick TH, Reid CM, Sanderson JE, Schmieder RE et al..  2009.  The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics. Clinical Research in Cardiology. 984. :21-33.[IF1.442]..
Peters R, Poulter R, Beckett N, Forette F, Fagard R, Potter J, Swift C, Anderson C, Fletcher A, Bulpitt CJ.  2009.  Cardiovascular and biochemical risk factors for incident dementia in the HYVET trial. Journal of Hypertension. In press. [IF 5.132].
Turnbull F, Arima H, Heeley E, Peiris D, Weekes A, Morgan C, Cass A, Anderson C, Patel A, Chalmers J.  2009.  Cardiovascular risk management among female and male patients in Australian General Practice: the AusHEART study. Proceedings of the 57th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand. <i>Heart, Lung and Circulation</i>. 2009;8(Suppl 3):S272
Heeley E, Peiris D, Patel A, Cass A, Weekes A, Morgan C, Anderson C, Chalmers J.  2009.  Cardiovascular risk perception and the evidence practice gap in Australian General Practice (the AusHEART study). Medical Journal of Australia. In press. [IF 3.320]
ADVANCE Collaborative Group, de Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A, Cooper M, Grobbee DE, Hackett M et al..  2009.  Cognitive function and risks of cardiovascular disease and hypoglycaemia in people with type 2 diabetes; the ADVANCE trial. Diabetelogia. 52:2329-36.[IF6.418].
Heeley E, Peiris D, Weekes A, Morgan C, Cass A, Anderson C, Patel A, Chalmers J.  2009.  Current prescribing of Blood Pressure lowering and statin therapies in Australian general practice according to risk level using new guidelines for cardiovascular risk assessment. Proceedings of the 57th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand. <i>Heart, Lung and Circulation</i>. 2009;18(Suppl 3):S280
Anderson C.  2009.  Declining stroke rates in southern Brazil: a positive result of socioeconomic development? Editorial Journal of Neurology, Neurosurgery & Psychiatry. 80:705.[IF4.622]..
Katzenellenbogen J, Vos T, Begg S, Codde J, Somerford P, Semmens J, Anderson C.  2009.  Disability Burden Due to Stroke in Western Australia: New Insights from Linked Data Sources. International Journal of Stroke. In press. [IF 2.000]
FIA Study Investigators, [Writing Committee], Broderick J, Brown RJ, Sauerbeck L, Hornung R, Huston JR, Woo D, Anderson C, Rouleau G et al..  2009.  Greater rupture risk for familial as compared to sporadic unruptured intracranial aneurysms. Stroke. Published online before print February 19, 2009, doi: 10.1161/STROKEAHA.108.542571. [IF 6.296]
Morgenstern LB, Claude Hemphill III J, Anderson C, Becker K, Broderick J, Sander Connolly Jr E, Greenberg SM, Huang JN, Loch Macdonald R, Messe SR et al..  2009.  Guidelines for the management of spontaneous intracerebral hemorrhage. Stroke. In press. [6.499]
ONTARGET Investigators, Writing Committee, Cowan BR, Young AA, Anderson C, Doughty RN, Krittayaphone R, Lonn E, Marwick TH, Reid CM et al..  2009.  Left ventricular mass and volume with Telmisartan, Ramipril, or with Diabetes Mellitus (From the Ongoing Telmisartan Alone and in combination with Rampipril Global Endpoint Trial [ONTARGET]). American Journal of Cardiology. 104:1484-9.[IF3.905].
Anderson C.  2009.  Medical management of acute intracerebral hemorrhage. Curr Opin Crit Care. 15:93–98.[IF3.318].
Heeley E, Peiris D, Weekes A, Cass A, Anderson C, Patel A, Chalmers J.  2009.  Prescribing of secondary prevention measures in Australian General Practice is lower in patients following an ischaemic stroke compared to those with a previous myocardial infarction. 6th Asia Pacific Conference Against Stroke.
Heeley E, Peiris D, Weekes A, Cass A, Anderson C, Patel A, Chalmers J.  2009.  Prescribing of secondary prevention measures in Australian General Practice is lower in patients following an ischaemic stroke compared to those with a previous myocardial infarction. Proceedings of the 57th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand. <i>Heart, Lung and Circulation</i>. 2009;18(Suppl 3):S280
Ninomiya T, Perkovic V, Verdon C, Barzi F , Cass A, Gallagher M, Jardine M, Anderson C, Chalmers J, Craig JC et al..  2009.  Proteinuria and stroke: a meta-analysis of cohort studies. American Journal of Kidney Diseases. 5:417-25.[IF3.981]..
INTERACT2 Investigators, Writing Committee, Delcourt C, Huang Y, Wang J, Heeley E, Lindley R, Stapf C, Tzourio C, Arima H et al..  2009.  The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an INTEnsive blood pressure Reduction in Acute Cerebral haemorrhage Trial (INTERACT2). International Journal of Stroke. In press. [IF 2.000]
Yusuf S, Pogue J, Teo K, Anderson C, Sleight P.  2009.  Telmisartan in high-risk patients intolerant of ACE inhibitors. Authors' reply . The Lancet. 373 :459[IF28.638]..
2008
Heeley E, Huang D, Wang J, Liu M, Jiang S, Jan S, Anderson C, ChinaQUEST Investigators.  2008.  Economic hardship from stroke in China. Proceedings of the 6th World Stroke Congress and X International Symposium on Thrombolysis and Acute Stroke Therapy. <i>International Journal of Stroke</i>. 2008;3(Suppl 1):62. [IF 1.917]

Latest News

Recently added pages

Our focus

George Institute sites